CROWDSTRIKE (CRWD) trades at $210.02, up 100% over the past year versus the S&P 500's 19.3% return. At $214.1 billion market value against $5.4 billion trailing revenue, the stock commands a 40x sales multiple. The question for equity investors is simple: does the growth runway justify the valuation? The data suggests yes.
The company reported $333 million in net new ARR for fiscal Q2 2027—up 51% year over year—marking the fourth consecutive quarter of ARR acceleration. Ending ARR reached $5.84 billion, up 25%. This is not a one-product story. AIDR, CrowdStrike's AI detection and response module, nearly tripled its ending ARR from the prior quarter. New modules—cloud, next-generation SIEM, next-generation identity—collectively hold $2.1 billion ending ARR and grew 39% year over year.
Falcon Flex, the flexible budget model, is the real catalyst. Customers on Flex represent $2.29 billion, or roughly 40% of total ending ARR, and grew 101% year over year. New Flex customers contributed 34% of net new ARR in the quarter. Customers who convert to Flex increase their ARR by 40% on average; those re-flexing twice show 53% expansion above their initial Flex commitment. This is expansion revenue, not churn.
CrowdStrike raised fiscal 2027 net new ARR guidance to approximately $1.35 billion at the midpoint—34% growth versus 22.5% guidance at the start of fiscal 2027. Management frames the growth driver clearly: AI agents require security as a prerequisite. With continuous operational capability and limited judgment, AI systems create new attack surfaces that legacy security tools cannot defend. CrowdStrike is not selling a trend—it is selling table stakes for AI infrastructure.
Profitability is improving. Trailing twelve-month operating margin stands at -2.2%, up from a -3.4% three-year average. Non-GAAP operating margin hit 25% in Q2. The company is scaling toward profitability while maintaining triple-digit net new ARR growth.
The 40x multiple is expensive only if growth deceleration is imminent. The evidence points the opposite direction: multi-product expansion, Falcon Flex stickiness, and a secular shift in buyer behavior all suggest growth re-acceleration, not peak. Implied volatility at 52 (76th percentile) prices continued price swings; patient capital should view dips as entry points, not warnings. Watch fiscal 2028 guidance on the next earnings call—if management raises net new ARR outlook again, this multiple can expand further.
